Our present findings demonstrate that vaccination against IL-33 elicits high titers of specific anti-IL-33 antibodies that markedly attenuate the development of airway inflammation and AHR, particularly within distal airways, in mice sensitized to HDM. Here, IL33 is linked to inflammatory response.